A new inter partes review proceeding at the Patent Trial and Appeal Board could draw close attention from patent owners, challengers, and counsel following the medical technology sector. In IPR2026-00341, filed June 12, 2026, the petition is styled Resmed Corp., signaling that ResMed is involved in a fresh PTAB dispute over the validity of an issued patent.
At this early stage, the public docket identifies the proceeding but may not yet fully reflect all underlying petition details, including the specific patent number, all real parties in interest, and the complete list of asserted prior-art grounds. That is common in newly filed PTAB matters, where practitioners often begin monitoring as soon as the case is opened to track later-added filings, exhibits, and any preliminary responses.
What is already clear is that this is an inter partes review, the PTAB’s principal vehicle for challenging patent claims on anticipation and obviousness grounds under 35 U.S.C. §§ 102 and 103 based on patents and printed publications. For IP counsel, the key filings to watch next will be the petition itself, the claim charts, expert declarations, and any patent owner preliminary response. Those materials will reveal which claims are under attack, what prior art the petitioner believes reads on the challenged claims, and whether the patent owner intends to fight institution on procedural, substantive, or discretionary grounds.
The identity of the challenged patent will matter. ResMed is a major player in sleep and respiratory care, and PTAB challenges involving medical-device or digital-health patents can have significance far beyond a single proceeding. Depending on the patent family, this case may implicate product design, reimbursement-sensitive technologies, connected-device ecosystems, or broader competitive positioning in a tightly regulated market.
Patent practitioners should also follow the case for institution-phase strategy. Newly filed IPRs often become useful barometers for how petitioners frame obviousness combinations, how they address discretionary denial issues, and how patent owners respond to technical and claim-construction arguments before the Board. If parallel district court litigation or related PTAB proceedings emerge, that could further raise the stakes and shape settlement leverage.
For now, this is a docket worth bookmarking early. As the record develops, IPR2026-00341 may offer practical lessons on PTAB petition drafting, medical-device prior art, and portfolio defense strategy for high-value patents.